Do I need to take Ixazomib/Enleri for life?

Ixazomib/Enleri (Ixazomib) is an oral proteasome inhibitor , mainly used to treat multiple myeloma (MM), usually in combination with other drugs, such as immunomodulators and steroids. Whether lifelong ixazomib treatment is required depends on the patient's specific circumstances, disease progression, and physician recommendations.

For patients with multiple myeloma, the goals of treatment are to control disease progression and improve quality of life. Initial treatment may last for a while, followed by a maintenance phase. At this stage, your doctor may recommend continuing ixazomib to reduce the risk of recurrence. However, whether to take it for life is not absolute. Factors such as the patient's physiological condition, drug tolerance and side effects will all affect this decision.

In many cases, doctors will adjust the medication regimen based on how the patient responds during treatment. If a patient's symptoms improve after treatment with ixazomib without serious side effects, the doctor may recommend continuing maintenance treatment. However, if the patient experiences significant side effects or the condition is effectively controlled, the doctor may consider reducing the frequency of medication or suspending treatment.

It is worth noting that long-term use of ixazomib may cause side effects, including but not limited to nausea, diarrhea, fatigue, and thrombocytopenia. Therefore, it is very necessary to conduct regular physical examinations and monitor blood indicators while continuing to use this drug. This helps potential side effects be detected and dealt with promptly. At the same time, patients should also actively communicate with doctors and provide feedback on their physical conditions so that doctors can make corresponding adjustments.

In some studies, combination therapy with ixazomib combined with other drugs has been shown to be effective in prolonging patients' progression-free survival (PFS). Therefore, many doctors will recommend maintenance therapy after initial treatment in the hope of maximizing control of disease progression.